Press Releases 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Eagle Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference 12/21/22 Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY® in Combination with Pembrolizumab and Platinum Chemotherapy 12/19/22 Eagle Pharmaceuticals Reaches Settlement Agreement with Accord Healthcare, Inc. Related to BENDEKA® (bendamustine hydrochloride) 12/12/22 Eagle Pharmaceuticals’ Investor Day to Focus on Acute Care Products and Pipeline Programs; Tuesday, December 6, 2022, at 8:00am ET at the Lotte New York Palace 12/1/22 Eagle Pharmaceuticals’ Investor Day to Feature World-Renowned KOLs on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel 11/16/22 Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia 11/14/22 Correcting & Replacing: Eagle Pharmaceuticals Reports Third Quarter 2022 Results 11/9/22 Eagle Pharmaceuticals to Host Third Quarter 2022 Financial Results on November 7, 2022 10/31/22 SAVE THE DATE: Eagle Pharmaceuticals to Host Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel 10/19/22 Eagle Pharmaceuticals Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Treatment of Severe Community-Acquired Bacterial Pneumonia 10/12/22 Pagination Current page 1 Page 2 Page 3 Page 4 Next page Last page
